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The authors reply: In response to Stanford 
et al.: after the exclusion of patients receiving in-
sulin, the median gestational weight gain among 
the women in our study was lower in the met-
formin group than in the placebo group (4.6 kg 
[interquartile range, 1.3 to 7.2] vs. 6.3 kg [inter-
quartile range, 2.9 to 9.2], P<0.001). In an evalu-
ation of changes in postpartum weight from the 
initial antenatal visit, the median gestational 
weight loss was higher in the metformin group 
than in the placebo group (1.9 kg [interquartile 
range, −5.1 to 0.2] vs. 0 kg [interquartile range, 
−3.9 to 1.5], P = 0.02). We agree that metformin 
might reduce the risk of long-term obesity in 
these women.
In response to Sahin and Corapcioglu: the 
American Diabetes Association classifies metfor-
min as a category B drug (i.e., no evidence of 
risk in humans) during pregnancy. In the United 
Kingdom, metformin is recommended by the 
National Institute for Health and Care Excel-
lence.1 There is no evidence of an increase in 
congenital malformations (including testicular 
abnormalities or defects in growth or motor 
development) in babies born to mothers treated 
with metformin.2,3 Blood-pressure results in a 
large cohort of 2-year-old children showed no 
differences between those whose mothers had 
received insulin and those whose mothers had 
received metformin.4 Active B
12
 (holotranscobal-
amin) and methylmalonic acid are better mea-
sures of vitamin B
12
 status than are serum levels 
and do not appear to be pathologically altered in 
patients with type 2 diabetes after metformin 
treatment.5
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Transient Smartphone “Blindness”
To the Editor: Transient monocular vision loss 
is a common clinical presentation, and the cause 
is not always thromboembolic.1 We present two 
cases in which careful history taking established 
a benign cause (for the case histories, see the 
Supplementary Appendix, available with the full 
text of this letter at NEJM.org).
A 22-year-old woman presented with a several 
months’ history of recurrent impaired vision in 
the right eye that occurred at night. The results 
of ophthalmic and cardiovascular examinations 
were normal. Vitamin A levels and the results of 
magnetic resonance angiography, echocardiog-
raphy, and a thrombophilia screening were also 
normal.
The second case involved a 40-year-old woman 
who presented with a 6-month history of recur-
rent monocular visual impairment on waking, 
lasting up to 15 minutes. The results of investi-
gations for a vascular cause were again normal. 
Aspirin therapy had been commenced.
When the patients were seen in our neuro-
ophthalmic clinic, detailed history taking re-
vealed that symptoms occurred only after several 
minutes of viewing a smartphone screen, in the 
dark, while lying in bed (before going to sleep in 
the first case and after waking in the second). 
Both patients were asked to experiment and re-
cord their symptoms. They reported that the 
symptoms were always in the eye contralateral 
to the side on which the patient was lying.
We hypothesized that the symptoms were due 
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to differential bleaching of photopigment, with 
the viewing eye becoming light-adapted while the 
eye blocked by the pillow was becoming dark-
adapted. Subsequently, with both eyes uncovered 
in the dark, the light-adapted eye was perceived 
to be “blind.” The discrepancy lasted several 
minutes, reflecting the time course of scotopic 
recovery after a bleach.2-4
In a study approved by a research ethics com-
mittee, two of the authors monocularly viewed a 
smartphone screen at arm’s length and quanti-
fied the time course of recovery of sensitivity in 
the dark both psychophysically and electrophysi-
ologically (Fig. 1). Visual sensitivity was appre-
ciably reduced after smartphone viewing, taking 
several minutes to recover, and this reduction 
in sensitivity was measurable at the level of the 
retina (Fig. 1B).
Although most people view screens binocu-
larly, people frequently use smartphones while 
lying down, when one eye can be inadvertently 
covered. Smartphones are now used nearly around 
the clock, and manufacturers are producing 
screens with increased brightness to offset back-
ground ambient luminance and thereby allow 
easy reading. Hence, presentations such as we 
describe are likely to become more frequent. Our 
cases show that detailed history taking and an 
understanding of retinal physiology can reassure 
both patient and doctor and can avoid unneces-
sary anxiety and costly investigations.
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Figue 1. Diminished Retinal Sensitivity after Smartphone 
Viewing.
In Panel A, the points plot visual threshold as a function 
of time after 0 or 20 minutes of smartphone viewing. 
The y axis plots the minimum intensity of light that  
the participant was able to see in the dark. Initially, the 
participant required a higher-intensity stimulus, indi-
cating low sensitivity; after approximately 20 minutes, 
the participant was able to see stimuli 100 times dim-
mer. In Panel B, the two traces show averaged electro-
retinographic responses to a dim flash of light that was 
delivered within a few minutes after 20 minutes  
of monocular smartphone viewing. The response am-
plitudes are very different, indicating that the eye that 
had viewed the smartphone had much lower retinal 
sensitivity than the eye that had been covered (this in-
terocular difference is what the patients perceived as 
transient monocular blindness). After approximately  
20 minutes, responses from both eyes were very simi-
lar (see the Supplementary Appendix).
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Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea
To the Editor: Resistance to all antimicrobial 
agents has developed in some Neisseria gonor-
rhoeae strains. Dual antimicrobial therapy (cef-
triaxone plus azithromycin) is a recommended 
first-line empirical treatment in many coun-
tries.1-3 We describe treatment failure with dual 
therapy in a patient with gonorrhea.
In December 2014, a heterosexual man pre-
sented to a sexual health clinic in the United 
Kingdom with a 2-week history of urogenital 
symptoms (Table 1). Ten days previously, he 
had returned from Japan, where his Japanese 
female partner had been treated for gonorrhea. 
He reported having no other recent sexual 
partners.
N. gonorrhoeae was detected in a urine spec-
imen and pharyngeal swab on nucleic acid 
amplification testing (Abbott RealTime CT/NG 
assay) and in a culture of a urethral specimen. 
All N. gonorrhoeae–positive specimens on nucleic 
acid amplification testing were also confirmed 
as positive with the use of a duplex polymerase-
chain-reaction (PCR) assay targeting the porA 
pseudogene and opa genes. According to the 
local laboratory, testing with the disk-diffusion 
method showed that the N. gonorrhoeae strain 
was resistant to cefuroxime, ciprofloxacin, and 
tetracycline. The patient declined to undergo 
testing for syphilis and human immunodefi-
ciency virus infection.
The patient received one dose of ceftriaxone 
intramuscularly at a dose of 500 mg plus 1 g 
of azithromycin orally.3 At the test of cure on 
day 15, a urine specimen was negative, but a 
pharyngeal swab remained positive for N. gonor-
rhoeae on the identical nucleic acid amplification 
test. The patient reported that he did not have 
sexual contact after treatment, and he did not 
return until day 79, when a pharyngeal swab 
was positive for N. gonorrhoeae on the nucleic acid 
amplification test.
On day 98, N. gonorrhoeae was detected in a 
pharyngeal sample on the nucleic acid amplifi-
cation test and culture. The patient received 
one dose of ceftriaxone at a dose of 1 g intra-
muscularly plus azithromycin at a dose of 2 g 
orally.3 At the test of cure on day 112, the 
pharyngeal specimen was negative (according 
to the nucleic acid amplification test). Initial pre-
treatment specimens were unavailable for fur-
ther analysis.
The N. gonorrhoeae species was verified with 
the use of the Phadebact Monoclonal GC Test 
and matrix-assisted laser desorption ionization–
time of flight mass spectrometry. Antimicrobial 
susceptibility testing with the use of Etest 
showed that the strain was resistant to ceftriax-
one, azithromycin, cefixime, cefotaxime, peni-
cillin, tetracycline, and ciprofloxacin, but it was 
susceptible to spectinomycin. Whole-genome 
sequencing of one isolate with the use of 
 Illumina MiSeq (BioProject accession number 
PRJNA305360) and conventional sequencing iden-
tified N. gonorrhoeae multilocus sequence type 
ST1901 and a new N. gonorrhoeae multiantigen 
sequence type ST12133 in all specimens (the 
isolate and PCR specimens). Resistance determi-
nants,1 mosaic penicillin-binding protein 2 X 
(which decreases ceftriaxone target affinity), 
deletion of one adenine in the mtrR promoter 
(which increases MtrCDE efflux of ceftriaxone 
and azithromycin), and penB (which decreases 
PorB influx of ceftriaxone and azithromycin) 
were detected in all specimens.
The patient was considered to have treatment 
failure because the post-treatment isolate was 
resistant to ceftriaxone and azithromycin, all 
specimens contained resistance determinants 
and identical sequence types, and reinfection 
was deemed to be unlikely. The N. gonorrhoeae 
strain that caused the failure belonged to the 
identical N. gonorrhoeae multiantigen sequence 
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